Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bloomberg Natural Gas ETF vs Revvity Inc — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.61, while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none, and Revvity Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BOIL | RVTY | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $87.24 | $117.75 |
52-Week Low | $18.74 | $82.26 |
Market Cap | — | $12.91B |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOIL trades at $20.73, showing minimal daily movement with a 0.1% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators remain neutral. The stock faces resistance at $21 with support at $20. Recent corporate actions include a 1:2 stock split scheduled for May 28, 2026. Natural gas market volatility and weather-dependent demand continue to influence price movements.
The outlook remains cautious given bearish technical signals and natural gas market uncertainty. Investment opportunities exist for tactical traders during volatility spikes, but risks include weather-dependent demand fluctuations and production increases. The stock split may improve liquidity but doesn't alter fundamental valuation. Investors should monitor EIA storage reports and weather forecasts as key catalysts.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
